Biomarker Discovery Outsourcing Services Market To Reach $76.3 Billion By 2033

Biomarker Discovery Outsourcing Services Market Growth & Trends

The global biomarker discovery outsourcing services market size is expected to reach USD 76.3 billion by 2033, registering a CAGR of 21.1% from 2026 to 2033, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market.

Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth. Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research. 

 Request a free sample copy or view report summary: Biomarker Discovery Outsourcing Services Market Report

Biomarker Discovery Outsourcing Services Market Report Highlights

• By biomarker type, the surrogate endpoints segment led the market with the largest revenue share of 54.5% in 2025. The predictive biomarkers segment is projected to register the fastest CAGR during the forecast period.

• By therapeutic area, the oncology segment led the market with the largest revenue share of 34.7% in 2025. The autoimmune diseases segment is projected to register the fastest CAGR during the forecast period.

• By discovery phase, the biomarker identification segment led the market with the largest revenue share of 28.6% in 2025.The biomarker validation segment is projected to register the fastest CAGR during the forecast period.

• By end-use, the biotechnology companies segment led the market with the largest revenue share of 42.5% in 2025. The pharmaceutical companies segment is projected to register the fastest CAGR during the forecast period.

• North America biomarker discovery outsourcing services market led with the largest revenue share of 43.8% in 2025.

Biomarker Discovery Outsourcing Services Market Segmentation

Grand View Research has segmented global biomarker discovery outsourcing services market report based on biomarker type, therapeutic area, discovery phase, end-use, and region:

Biomarker Discovery Outsourcing Services Biomarker Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Predictive Biomarkers

• Prognostic Biomarkers

• Safety Biomarkers

• Surrogate Endpoints

Biomarker Discovery Outsourcing Services Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)

• Oncology

• Neurology

• Cardiology

• Autoimmune Diseases

• Other Therapeutic Area

Biomarker Discovery Outsourcing Services Discovery Phase Outlook (Revenue, USD Billion, 2021 - 2033)

• Biomarker Identification

• Biomarker Validation

• Biomarker Profiling

• Biomarker Panel Development

• Biomarker Selection

Biomarker Discovery Outsourcing Services End-use Outlook (Revenue, USD Billion, 2021 - 2033)

• Pharmaceutical Companies

• Biotechnology Companies

• Other End Use

Biomarker Discovery Outsourcing Services Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players of Biomarker Discovery Outsourcing Services Market

• LabCorp

• Charles River Laboratories International, Inc.

• Eurofins Scientific

• Celerion

• ICON plc

• Parexel International (MA) Corporation

• Proteome Sciences

• GHO Capital

• Thermo Fisher Scientific Inc.

• Evotec